ANA MARIA KONDO IGAI
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/57 - Laboratório de Fisiologia Obstétrica, Hospital das Clínicas, Faculdade de Medicina
LIM/57 - Laboratório de Fisiologia Obstétrica, Hospital das Clínicas, Faculdade de Medicina
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- Obstetric antiphospholipid syndrome(2021) BARROS, Venina Isabel Poco Viana Leme de; IGAI, Ana Maria Kondo; OLIVEIRA, Andre Luiz Malavasi Longo de; TERUCHKIN, Marcelo Melzer; ORSI, Fernanda Andrade
- Risk assessment of venous thromboembolism and thromboprophylaxis in pregnant women hospitalized with cancer: Preliminary results from a risk score(2018) HASE, Eliane Azeka; BARROS, Venina Isabel Poco Viana Leme de; IGAI, Ana Maria Kondo; FRANCISCO, Rossana Pulcinelli Vieira; ZUGAIB, MarceloOBJECTIVES: Hospitalized patients with cancer are at high risk of developing venous thromboembolism, and the risk increases with pregnancy. The aim of this study was to apply a thromboprophylaxis protocol with a venous thromboembolism risk score for hospitalized pregnant women with cancer and to evaluate the effects on maternal morbidity and mortality. METHODS: A longitudinal and prospective study was conducted from December 2014 to July 2016. The venous thromboembolism risk score was modified from the guidelines of the Royal College of Obstetricians and Gynaecologists. Patients were classified as low (score <3) or high risk (score >= 3). The high-risk group received thromboprophylaxis with low-molecular-weight heparin, unless the patient had a contraindication for anticoagulation. One patient could have undergone more than one evaluation. RESULTS: Fifty-two ratings were descriptively analyzed: 34 (65.4%) were classified as high risk, and 28/34 (82.3%) received low-molecular-weight heparin, 1 received unfractionated heparin, and 5 did not receive intervention. Most patients (23/52; 44.2%) had breast cancer. The main risk factors for venous thromboembolism in the high-risk group were chemotherapy (within 6 months; 22/34; 64.7%). No patient exhibited venous thromboembolism, adverse effects of anticoagulation or death up to three months after hospitalization. CONCLUSIONS: Most pregnant women with cancer had a high risk for venous thromboembolism at the time of hospitalization. Breast cancer was the most prevalent cancer, and recent chemotherapy was the main risk factor for anticoagulation. The application of a thromboprophylaxis protocol and determination of a venous thromboembolism risk score for these patients was useful for the prevention of maternal morbidity and mortality due to venous thromboembolism.
- Abnormal uterine bleeding and chronic iron deficiency Number 11-December 2022(2022) BARROS, Venina Viana de; HASE, Eliane Azeka; SALAZAR, Cristiano Caetano; IGAI, Ana Maria Kondo; ORSI, Fernanda Andrade; MARGARIDO, Paulo Francisco Ramos
- Resultados gestacionais e trombofilias em mulheres com historia de obito fetal de repeticao(2014) BARROS, Venina Isabel Poco Viana Leme de; IGAI, Ana Maria Kondo; ANDRES, Marina de Paula; FRANCISCO, Rossana Pulccinelli Vieira; ZUGAIB, MarceloPURPOSE: To evaluate pregnancy outcome and thrombophilia frequency in women with recurrent fetal death. METHODS: Evaluation of obstetric outcomes in a retrospective cohort of pregnant women with recurrent stillbirth after the 20th week, from 2001 to 2013. Antithrombin activity, protein C and S activity, factor V Leiden, prothrombin gene mutation and antiphospholipid syndrome were analyzed. RESULTS: We included 20 patients who had recurrent fetal death. Thrombophilia were found in 11 of them, 7 diagnosed with antiphospholipid syndrome, 3 with protein S deficiency and 1 with prothrombin gene mutation. All of them were treated with subcutaneous heparin (unfractionated heparin or enoxaparina) and 14 of them with acetylsalicylic acid (AAS) during pregnancy. Obstetric complications occurred in 15 patients and included: intrauterine fetal growth restriction (25%), placenta previa (15%), reduced amniotic fluid index (25%), severe preeclampsia (10%), fetal distress (5%), and stillbirth (5%). The mean gestational age at delivery was 35.8±3.7 weeks and newborn weight averaged 2,417.3±666.2 g. CONCLUSION: Thrombophilia screening should be performed in all pregnant women with recurrent fetal death after the 20th week as a way to identify possible causal factors suitable for treatment.
conferenceObject Risk assessment of venous thromboembolism (VTE) and thromboprophylaxis in pregnant women hospitalized with cancer(2016) HASE, E.; BARROS, V; IGAI, A. M.; NAKAMURA, A.; FRANCISCO, R.- Venous thromboembolism risk score during hospitalization in pregnancy: results of 10694 prospective evaluations in a clinical trial(2023) BARROS, Venina Isabel Poco Viana Leme de; IGAI, Ana Maria Kondo; BAPTISTA, Fernanda Spadotto; BORTOLOTTO, Maria Rita de Figueiredo Lemos; PERES, Stela Verzinhasse; FRANCISCO, Rossana Pulcinelli VieiraObjectives: Hospitalization during pregnancy and childbirth increases the risk of Venous Thromboembolism Risk (VTE). This study applied a VTE risk score to all hospitalized pregnant women to ascertain its effectiveness in pre -venting maternal death from VTE until 3 months after discharge.Methods: In this interventional study, patients were classified as low-or high-risk according to the VTE risk score (Clinics Hospital risk score). High-risk patients (score & GE; 3) were scheduled for pharmacological Thromboprophy-laxis (TPX). Interaction analysis of the main risk factors was performed using Odds Ratio (OR) and Poisson regres-sion with robust variance.Results: The data of 10694 cases (7212 patients) were analyzed; 1626 (15.2%, 1000 patients) and 9068 (84.8%, 6212 patients) cases were classified as high-risk (score & GE; 3) and low-risk (score < 3), respectively. The main risk factors (Odds Ratio, 95% Confidence Interval) for VTE were age & GE; 35 and < 40 years (1.6, 1.4-1.8), parity & GE; 3 (3.5, 3.0-4.0), age & GE; 40 years (4.8, 4.1-5.6), multiple pregnancies (2.1, 1.7-2.5), BMI & GE; 40 kg/m2 (5.1, 4.3-6.0), severe infection (4.1, 3.3-5.1), and cancer (12.3, 8.8-17.2). There were 10 cases of VTE: 7/ 1636 (0.4%) and 3/9068 (0.03%) in the high-and low-risk groups, respectively. No patient died of VTE. The inter-vention reduced the VTE risk by 87%; the number needed to treat was 3.Conclusions: This VTE risk score was effective in preventing maternal deaths from VTE, with a low indication for TPX. Maternal age, multiparity, obesity, severe infections, multiple pregnancies, and cancer were the main risk factors for VTE.